SNDX SYNDAX PHARMACEUTICALS INC Capital Structure Changes 8-K Filing 2023 - Termination of Sales Agreement and New Sales Agreement Syndax Pharmaceuticals terminated a sales agreement with TD Cowen and entered into a new sales agreement with them, allowing Syndax to sell Placement Shares with an aggregate offering price of up to $200 million.Get access to all SEC 8-K filings of the SYNDAX PHARMACEUTICALS INC